Akari Therapeutics Plc AKTX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$7.37 down $0.38, 4.90% at close Nov 6
Last close · Previous close $7.75
- Market cap
- At the Nov 6 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$7.37down $1.02, 12.16%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$7.75Nov 5
- Volume53.06KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume49.44KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.02 to $29.32; now $7.37
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
AKTX trailed the S&P 500 in all 7 periods.
| Period | AKTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AKTX: down 12.2% S&P 500: down 5.6% | AKTX trailed the S&P 500 by 6.6 percentage points Trailed |
| 3M | AKTX: down 8.8% S&P 500: down 4.1% | AKTX trailed the S&P 500 by 4.7 percentage points Trailed |
| YTD | AKTX: down 36.2% S&P 500: up 8.7% | AKTX trailed the S&P 500 by 44.9 percentage points Trailed |
| 1Y | AKTX: down 70.1% S&P 500: up 10.9% | AKTX trailed the S&P 500 by 81.0 percentage points Trailed |
| Long term | ||
| 3Y | AKTX: down 95.0% S&P 500: up 75.0% −63.2% vs +20.5% a year | AKTX trailed the S&P 500 by 170.0 percentage points Trailed |
| 5Y | AKTX: down 99.5% S&P 500: up 67.8% −64.7% vs +10.9% a year | AKTX trailed the S&P 500 by 167.3 percentage points Trailed |
| 10Y | AKTX: down 99.9% S&P 500: up 313.1% −49.6% vs +15.2% a year | AKTX trailed the S&P 500 by 413.0 percentage points Trailed |
$10,000 invested in AKTX 10 years ago (Nov 4, 2016) would be worth about $11 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
AKTX trailed the S&P 500 in all 7 periods.
| Period | AKTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AKTX: down 12.2% S&P 500: down 5.6% | AKTX trailed the S&P 500 by 6.6 percentage points Trailed |
| 3M | AKTX: down 8.8% S&P 500: down 4.3% | AKTX trailed the S&P 500 by 4.5 percentage points Trailed |
| YTD | AKTX: down 36.2% S&P 500: up 7.8% | AKTX trailed the S&P 500 by 44.0 percentage points Trailed |
| 1Y | AKTX: down 70.1% S&P 500: up 9.7% | AKTX trailed the S&P 500 by 79.8 percentage points Trailed |
| Long term | ||
| 3Y | AKTX: down 95.0% S&P 500: up 68.8% −63.2% vs +19.1% a year | AKTX trailed the S&P 500 by 163.8 percentage points Trailed |
| 5Y | AKTX: down 99.5% S&P 500: up 56.9% −64.7% vs +9.4% a year | AKTX trailed the S&P 500 by 156.4 percentage points Trailed |
| 10Y | AKTX: down 99.9% S&P 500: up 252.6% −49.6% vs +13.4% a year | AKTX trailed the S&P 500 by 352.5 percentage points Trailed |
$10,000 invested in AKTX 10 years ago (Nov 4, 2016) would be worth about $11 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$25,200.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Sep 21, 2015.
Stock splits
2
Latest: 1-for-40 on . Share counts adjust after each split.
Both splits
- 1-for-40
- 1-for-20
Valuation
Financials
About Akari Therapeutics Plc
nan
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AKTX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AKTX stock FAQ
What is AKTX stock’s price today?
Akari Therapeutics (AKTX) traded at $7.37 at the close on , down $0.38 (4.90%) from the previous close of $7.75. Over the past 52 weeks it has traded between $3.02 and $29.32.
If you invested $1,000 in AKTX 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in AKTX on would be worth about $1 at the close on , a total return of −99.9%. The same $1,000 would be worth $5 if invested five years ago and $299 if invested one year ago. Past performance doesn’t predict future returns.
Does AKTX pay a dividend?
Akari Therapeutics hasn’t paid a dividend in the last twelve months.
What is AKTX’s 52-week high and low?
Over the past 52 weeks AKTX has traded as low as $3.02 and as high as $29.32. At $7.37 at the close on , it is 74.9% below that high and 144.4% above the low.
What is AKTX’s all-time high?
AKTX’s highest closing price was $25,200.00 on , adjusted for stock splits. At $7.37 at the close on , it is 100.0% below that record.
Has AKTX stock ever split?
Yes, twice: 1-for-20 on ; 1-for-40 on .
How has AKTX stock performed?
Including dividends and measured to the close on , AKTX has returned −36.2% so far this year and −70.1% over the past year, and −99.5% over five years (−64.7% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Akari Therapeutics in?
Akari Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does AKTX trade on?
Akari Therapeutics trades on the Nasdaq under the ticker symbol AKTX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.